FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.

Vallet-Pichard A; Mallet V; Pol S

doi:10.1002/hep.21334

FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.

MeSH — NLM indexing Biopsy Hepatitis C, Chronic / complications Hepatitis C, Chronic / pathology Humans Liver Cirrhosis / complications Liver Cirrhosis / pathology Prognosis ROC Curve Reproducibility of Results Severity of Illness Index

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Fibrotest Actitest Letter Independent Group France

Authors (3)

Citation

Vallet-Pichard A, Mallet V, Pol S. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology. 2006;44(3):769; author reply 769-70. doi:10.1002/hep.21334.

Identifiers

DOI: 10.1002/hep.21334
PMID: 16941681

Tests

Liver diseases

Liver injuries

Comparisons

Subjects

Region

FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.

More by Vallet-Pichard A

FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

More on the same topic

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Toward non-invasive assessment strategies in autoimmune hepatitis.